Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Democrats’ Drug Pricing Bills Echo Trump Ideas But Broad Republican Support Unlikely

Executive Summary

Upcoming House Oversight Committee hearing on drug pricing offers a chance for fireworks, but broader prospects for new Democratic pricing legislation seem limited.

Related Content

How Much Can Trump’s Childhood Cancer Funding Proposal Boost Drug Approvals?
PhRMA Adds Genentech, Gilead To Its Ranks Ahead Of House Democrats’ Drug Pricing Scrutiny
Biopharma Predicts ‘Significant’ R&D Reductions With Medicare IPI Model
Democrat-Controlled House Will Turn Up The Volume On Drug Pricing
Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
Drug Importation Can Be Triggered By 'Excessive' Price Increases; Now US FDA Has To Decide What That Means
Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan
Sen. Cassidy Suggests Importing Generics From EU To Pressure US Prices
Drug Importation Blocked But Not Forgotten As User Fee Bill Clears Senate Cmte
FDA Can Help On Drug Prices – Except When It Can't, Califf Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts